Innovative Approaches to Molecular Pathogenesis and Therapy of Lymphoid Malignancies: 2nd Edition

Dear Colleagues,

Lymphoid malignancies include an array of distinct and biologically complex neoplastic disorders of lymphoid (B-, T-, and NK-) cell origin. Basic, translational, and clinical research continues to enhance our understanding of lymphoid neoplasm pathogenesis, drug resistance, and relapse. Molecular dependencies identified in each of these processes have allowed clinicians to refine disease classification, diagnosis, and therapeutic strategies. However, there is still a great need for innovative approaches to targeted therapy development in order to actualize well-informed, personalized medicine for patients.

This Special Issue welcomes original research and review articles that address the molecular factors contributing to lymphoid malignancy pathogenesis and/or therapeutically targeting such factors. These include, but are not limited to, genetic, epigenetic, signalling, metabolic, and immune contributors. Topics of particular interest include the following:

• Mechanistic studies of oncogenic events (genetic or epigenetic) that contribute to disease pathogenesis;
• Studies that characterize tumor microenvironment cancer cell dependencies (factors that support cancer cell survival/growth or contribute to evasion of anti-tumor immunity) or therapeutically targeting such factors;
• Translational studies investigating novel therapeutic approaches, including small molecule inhibitors or antibody therapies;
• Studies that utilize drug-resistance models;
• Innovative therapeutic formulations, delivery modes, or combination strategies;
• Methods for early detection or improved classification of disease.

We look forward to your contributions to this Special Issue.

Dr. Sara Elgamal
Dr. Dalia El-Gamal
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.